Di Cai

Di Cai is a Partner and Research Analyst at Sanders Capital, LLC in New York, supporting the firm's global investment strategies. At Sanders Capital, she focuses on investment research with a particular expertise in healthcare, personalized medicine, and Asia-related opportunities, drawing from her scientific background and previous roles in venture and growth equity. She is responsible for evaluating sector-specific trends and identifying investment opportunities, especially those involving healthcare innovation and Asian markets.

Before joining Sanders Capital in 2013, Di Cai held positions as a Summer Associate at The Carlyle Group on the Asia Growth Equity Team and at Kleiner Perkins with their China healthcare investment team. Her earlier career included senior research roles in personalized medicine and cancer prognostics, notably at The Scripps Research Institute and the University of Texas Southwestern Medical Center, where she led pioneering studies and discovered novel biomarkers for lung cancer prognosis.

Dr. Cai holds an MBA from The Wharton School and a Ph.D. from The University of Texas Southwestern Medical Center at Dallas. She is recognized for leveraging her scientific expertise in investment analysis, notably integrating ESG and climate considerations into research. Di Cai serves on advisory boards such as the Serica Initiative, contributing to cross-cultural finance and healthcare investment dialogue.